{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:52:28Z","timestamp":1787503948546,"version":"build-2736575974"},"reference-count":240,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Heinrich Heine University D\u00fcsseldorf"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Inflammatory neuromuscular disorders encompass a diverse group of immune-mediated diseases with varying clinical manifestations and treatment responses. The identification of specific biomarkers has the potential to provide valuable insights into disease pathogenesis, aid in accurate diagnosis, predict disease course, and monitor treatment efficacy. However, the rarity and heterogeneity of these disorders pose significant challenges in the identification and implementation of reliable biomarkers. Here, we aim to provide a comprehensive review of biomarkers currently established in Guillain-Barr\u00e9 syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), and idiopathic inflammatory myopathy (IIM). It highlights the existing biomarkers in these disorders, including diagnostic, prognostic, predictive and monitoring biomarkers, while emphasizing the unmet need for additional specific biomarkers. The limitations and challenges associated with the current biomarkers are discussed, and the potential implications for disease management and personalized treatment strategies are explored. Collectively, biomarkers have the potential to improve the management of inflammatory neuromuscular disorders. However, novel strategies and further research are needed to establish clinically meaningful biomarkers.<\/jats:p>","DOI":"10.3390\/cells12202456","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T10:47:32Z","timestamp":1697366852000},"page":"2456","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Current Biomarker Strategies in Autoimmune Neuromuscular Diseases"],"prefix":"10.3390","volume":"12","author":[{"given":"Menekse","family":"Oeztuerk","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Henes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Schroeter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Quint","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Theissen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-8650","authenticated-orcid":false,"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.2016.2240","article-title":"Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions","volume":"315","author":"Robb","year":"2016","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Islam, Z., van Belkum, A., Wagenaar, J.A., Cody, A.J., de Boer, A.G., Tabor, H., Jacobs, B.C., Talukder, K.A., and Endtz, H.P. (2009). Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barr\u00e9 syndrome in Bangladesh. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007257"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1128\/IAI.00872-06","article-title":"Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes","volume":"75","author":"Godschalk","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jneuroim.2011.09.004","article-title":"Campylobacter jejuni DNA-binding protein from starved cells in Guillain-Barr\u00e9 syndrome patients","volume":"240\u2013241","author":"Kawamura","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1007\/s10072-021-05314-y","article-title":"Expression pattern of matrix metalloproteinases-2 and -9 and their tissue inhibitors in patients with chronic inflammatory demyelinating polyneuropathy","volume":"42","author":"Cosentino","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/jnnp.2004.052282","article-title":"T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"76","author":"Csurhes","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0165-5728(01)00307-1","article-title":"Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies","volume":"116","author":"Kwa","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0165-5728(99)00269-6","article-title":"Anti-PMP22 antibodies in patients with inflammatory neuropathy","volume":"104","author":"Gabriel","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jnnp.2006.106617","article-title":"Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy","volume":"78","author":"Inglis","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/jnnp.2007.123943","article-title":"Immune responses to myelin proteins in Guillain-Barr\u00e9 syndrome","volume":"79","author":"Makowska","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1523\/JNEUROSCI.19-09-03396.1999","article-title":"Peripheral myelin protein 22 and protein zero: A novel association in peripheral nervous system myelin","volume":"19","author":"Ehrhardt","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-510X(97)00178-0","article-title":"T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barr\u00e9 syndrome","volume":"153","author":"Dahle","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jnnp-2020-324445","article-title":"CSF sphingomyelin: A new biomarker of demyelination in the diagnosis and management of CIDP and GBS","volume":"92","author":"Capodivento","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1212\/WNL.55.12.1828","article-title":"Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases","volume":"55","author":"Nagai","year":"2000","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10571-007-9257-7","article-title":"Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barr\u00e9 syndrome","volume":"28","author":"Yang","year":"2008","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_18","first-page":"5177","article-title":"Identification of CSF biomarkers by proteomics in Guillain-Barr\u00e9 syndrome","volume":"15","author":"Li","year":"2018","journal-title":"Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11033-008-9228-1","article-title":"Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barr\u00e9 Syndrome by a proteomical approach","volume":"36","author":"Yang","year":"2009","journal-title":"Mol. Biol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1085-9489.2004.009209o.x","article-title":"14-3-3 protein in the CSF of inflammatory peripheral neuropathies","volume":"9","author":"Bersano","year":"2004","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1212\/01.wnl.0000249150.98891.d1","article-title":"Detection of CSF 14-3-3 protein in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Bersano","year":"2006","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1212\/NXI.0000000000001031","article-title":"Interleukin 8, a Biomarker to Differentiate Guillain-Barr\u00e9 Syndrome From CIDP","volume":"8","author":"Breville","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-510X(98)00331-1","article-title":"Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barr\u00e9 and Fisher\u2019s syndromes: Their association with cranial nerve dysfunction","volume":"164","author":"Koga","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1212\/WNL.0000000000000577","article-title":"Antibodies to single glycolipids and glycolipid complexes in Guillain-Barr\u00e9 syndrome subtypes","volume":"83","author":"Shahrizaila","year":"2014","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"564098","DOI":"10.1155\/2015\/564098","article-title":"Biomarkers of Guillain-Barr\u00e9 Syndrome: Some Recent Progress, More Still to Be Explored","volume":"2015","author":"Wang","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/jnnp-2011-300309","article-title":"Antiganglioside antibodies are associated with axonal Guillain-Barr\u00e9 syndrome: A Japanese-Italian collaborative study","volume":"83","author":"Sekiguchi","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.410380516","article-title":"Anti-ganglioside GM1 antibodies in Guillain-Barr\u00e9 syndrome and their relationship to Campylobacter jejuni infection","volume":"38","author":"Rees","year":"1995","journal-title":"Ann. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","article-title":"Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barr\u00e9 syndrome","volume":"40","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1212\/WNL.43.10.1911","article-title":"Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barr\u00e9 syndrome: Clinical and immunohistochemical studies","volume":"43","author":"Chiba","year":"1993","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/brain\/awab014","article-title":"Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"144","author":"Fehmi","year":"2021","journal-title":"Brain"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype","volume":"7","author":"Cortese","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/acn3.248","article-title":"Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy","volume":"2","author":"Ogata","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/brain\/awv054","article-title":"Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia","volume":"138","author":"Miura","year":"2015","journal-title":"Brain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2392","DOI":"10.1212\/WNL.0000000000012932","article-title":"Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes","volume":"97","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/WNL.0b013e31827689ad","article-title":"Neurofascin as a target for autoantibodies in peripheral neuropathies","volume":"79","author":"Ng","year":"2012","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/brain\/awn281","article-title":"Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis","volume":"132","author":"Lonigro","year":"2009","journal-title":"Brain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1242\/jcs.104729","article-title":"Neurofilaments at a glance","volume":"125","author":"Yuan","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.wnl.0000237334.69665.92","article-title":"CSF neurofilament levels: A potential prognostic marker in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Petzold","year":"2006","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Godelaine, J., De Schaepdryver, M., Bossuyt, X., Van Damme, P., Claeys, K.G., and Poesen, K. (2021). Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Commun., 3.","DOI":"10.1093\/braincomms\/fcab018"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10072-012-1092-z","article-title":"Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barr\u00e9 syndrome","volume":"34","author":"Wang","year":"2013","journal-title":"Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/7651_2015_206","article-title":"Neurofilament Light Chain Determination from Peripheral Blood Samples","volume":"1304","author":"Limberg","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/ene.15428","article-title":"Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies","volume":"29","author":"Kmezic","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.880180407","article-title":"Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection","volume":"18","author":"Kusunoki","year":"1995","journal-title":"Muscle Nerve"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2013.11.016","article-title":"Clinical features in Guillain-Barr\u00e9 syndrome with anti-Gal-C antibody","volume":"337","author":"Samukawa","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_48","first-page":"2759","article-title":"Development of a new automated enzyme immunoassay for the determination of neuron-specific enolase","volume":"19","author":"Sterk","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1600-0404.1995.tb00450.x","article-title":"Cerebrospinal fluid levels of S-100b protein and neuron-specific enolase in chronic inflammatory demyelinating polyneuropathy","volume":"91","author":"Nagamatsu","year":"1995","journal-title":"Acta Neurol. Scand."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0404.1994.tb01628.x","article-title":"Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barr\u00e9 syndrome","volume":"89","author":"Mokuno","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0304-3940(98)00992-6","article-title":"Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease","volume":"261","author":"Kropp","year":"1999","journal-title":"Neurosci. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/clin.1998.4573","article-title":"Recovery from Guillain-Barr\u00e9 syndrome is associated with increased levels of neutralizing autoantibodies to interferon-gamma","volume":"88","author":"Elkarim","year":"1998","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"639712","DOI":"10.1155\/2013\/639712","article-title":"Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barr\u00e9 syndrome","volume":"2013","author":"Li","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/14728222.2014.882899","article-title":"Can IFN-\u03b3 be a therapeutic target in Guillain-Barr\u00e9 syndrome?","volume":"18","author":"Zhang","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1034\/j.1600-0404.2003.00179.x","article-title":"Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome","volume":"109","author":"Radhakrishnan","year":"2004","journal-title":"Acta Neurol. Scand."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1468-1331.2008.02261.x","article-title":"The role of IL-12 and TNF-alpha in AIDP and AMAN","volume":"15","author":"Deng","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"740947","DOI":"10.1155\/2014\/740947","article-title":"Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barr\u00e9 syndrome and downregulated by IVIg treatments","volume":"2014","author":"Li","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0165-5728(00)00460-4","article-title":"Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy","volume":"114","author":"Jander","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fnins.2019.00717","article-title":"Peripheral Blood and Cerebrospinal Fluid Cytokine Levels in Guillain Barr\u00e9 Syndrome: A Systematic Review and Meta-Analysis","volume":"13","author":"Sun","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1750-3639.2002.tb00459.x","article-title":"The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis","volume":"12","author":"Bao","year":"2002","journal-title":"Brain Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1750-3639.2008.00172.x","article-title":"Expression of interleukin-16 in sciatic nerves, spinal roots and spinal cords of experimental autoimmune neuritis rats","volume":"19","author":"Zhang","year":"2009","journal-title":"Brain Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cyto.2017.12.029","article-title":"IL-23\/IL-17 immune axis in Guillain Barr\u00e9 Syndrome: Exploring newer vistas for understanding pathobiology and therapeutic implications","volume":"103","author":"Debnath","year":"2018","journal-title":"Cytokine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-5728(98)00053-8","article-title":"Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha\/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage","volume":"87","author":"Hohnoki","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2014.12.017","article-title":"Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy","volume":"279","author":"Beppu","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jnnp.64.2.162","article-title":"Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barr\u00e9 syndrome: Decreased concentrations in the early course and increase with motor function","volume":"64","author":"Clair","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"120512","DOI":"10.1016\/j.jns.2022.120512","article-title":"Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barr\u00e9 syndrome","volume":"444","author":"Min","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acn3.331","article-title":"Terminal complement activation is increased and associated with disease severity in CIDP","volume":"3","author":"Quast","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s13311-022-01221-y","article-title":"The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies","volume":"19","author":"Querol","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/01.TA.0000130613.35877.75","article-title":"Raised serum S100B levels after acute bone fractures without cerebral injury","volume":"58","author":"Bellner","year":"2005","journal-title":"J. Trauma"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kim, M.J., Kim, J.H., Jung, J.H., Kim, S.E., Kim, H.S., Jang, M.K., Park, S.H., Lee, M.S., Suk, K.T., and Kim, D.J. (2023). Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030333"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cyto.2010.05.005","article-title":"The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barr\u00e9 syndrome from chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"Sainaghi","year":"2010","journal-title":"Cytokine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-5728(02)00393-4","article-title":"Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barr\u00e9 syndrome and experimental autoimmune neuritis","volume":"134","author":"Orlikowski","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/awf070","article-title":"Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: A central role for IP-10","volume":"125","author":"Kieseier","year":"2002","journal-title":"Brain"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp.73.3.320","article-title":"Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Mahad","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF02339236","article-title":"Increased serum levels of ICAM-1, ELAM-1 and TNF-alpha in inflammatory disorders of the peripheral nervous system","volume":"15","author":"Musso","year":"1994","journal-title":"Ital. J. Neurol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2965","DOI":"10.1002\/brb3.2965","article-title":"Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt\/mTOR\/NF-\u03baB signaling","volume":"13","author":"Feng","year":"2023","journal-title":"Brain Behav."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2016.10.014","article-title":"MicroRNA expression profiling in Guillain-Barr\u00e9 syndrome","volume":"301","author":"Lv","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"300060520904842","DOI":"10.1177\/0300060520904842","article-title":"Correlations between microRNA-146a and immunoglobulin and inflammatory factors in Guillain-Barr\u00e9 syndrome","volume":"48","author":"Huang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2305163","DOI":"10.1155\/2023\/2305163","article-title":"miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy","volume":"2023","author":"Dziadkowiak","year":"2023","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Heldal, A.T., Eide, G.E., Romi, F., Owe, J.F., and Gilhus, N.E. (2014). Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114060"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/01658107.2022.2037662","article-title":"Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies","volume":"46","author":"Behbehani","year":"2022","journal-title":"Neuroophthalmology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00415-020-10342-3","article-title":"Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: A matter of age?","volume":"268","author":"Monte","year":"2021","journal-title":"J. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kordas, G., Lagoumintzis, G., Sideris, S., Poulas, K., and Tzartos, S.J. (2014). Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108327"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneuroim.2007.07.018","article-title":"Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: A combination of immunoadsorbents results in increased efficiency","volume":"190","author":"Kostelidou","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.410100506","article-title":"Humoral immunity in myasthenia gravis: Biochemical characterization of acquired antireceptor antibodies and clinical correlations","volume":"10","author":"Tindall","year":"1981","journal-title":"Ann. Neurol."},{"key":"ref_87","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: Predominance of IgG subclasses 1 and 3","volume":"67","author":"Nielsen","year":"1987","journal-title":"Clin. Exp. Immunol"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"ref_89","first-page":"78","article-title":"Myasthenia gravis: Demonstration of membrane attack complex in muscle end-plates","volume":"5","author":"Fazekas","year":"1986","journal-title":"Clin. Neuropathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.1212\/NXI.0000000000001169","article-title":"Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916939109007633","article-title":"The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis","volume":"8","author":"Tzartos","year":"1991","journal-title":"Autoimmunity"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JND-180313","article-title":"Serum Acetylcholine Receptor Antibodies Before the Clinical Onset of Myasthenia Gravis","volume":"5","author":"Strijbos","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in \u2018seronegative\u2019 myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"120084","DOI":"10.1016\/j.jns.2021.120084","article-title":"Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis","volume":"432","author":"Mirian","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population","volume":"343","author":"Chang","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Fichtner, M.L., Hoarty, M.D., Vadysirisack, D.D., Munro-Sheldon, B., Nowak, R.J., and O\u2019Connor, K.C. (2022). Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264489"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-Associated Myasthenia Gravis: Clinical Features and Management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0896-6273(95)90146-9","article-title":"Receptor tyrosine kinase specific for the skeletal muscle lineage: Expression in embryonic muscle, at the neuromuscular junction, and after injury","volume":"15","author":"Valenzuela","year":"1995","journal-title":"Neuron"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","article-title":"MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation","volume":"268","author":"Stetefeld","year":"2021","journal-title":"J. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: Beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: Correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jneuroim.2014.09.013","article-title":"Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy","volume":"276","author":"Skriapa","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00415-022-11458-4","article-title":"Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis","volume":"270","author":"Kwon","year":"2023","journal-title":"J. Neurol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: Systematic review","volume":"91","author":"Lupica","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: A multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1296-e84","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"978997","DOI":"10.3389\/fneur.2022.978997","article-title":"Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Neurol"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00415-004-0479-z","article-title":"The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis","volume":"251","author":"Chen","year":"2004","journal-title":"J. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis","volume":"170","author":"Suzuki","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.autrev.2014.08.038","article-title":"Identification of a novel myositis-associated antibody directed against cortactin","volume":"13","author":"Juarez","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/nyas.13502","article-title":"Diagnostic utility of cortactin antibodies in myasthenia gravis","volume":"1412","author":"Illa","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"753247","DOI":"10.3389\/fimmu.2021.753247","article-title":"Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2020.00213","article-title":"Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine","volume":"11","author":"Sabre","year":"2020","journal-title":"Front. Immunol"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-Mi-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Liang, L., Zhang, Y.M., Chen, H., Ye, L.F., Li, S.S., Lu, X., Wang, G.C., and Peng, Q.L. (2020). Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis. Eur. J. Derm.","DOI":"10.1684\/ejd.2020.3750"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/cia2.12048","article-title":"Anti-Mi-2 antibody titers and cutaneous manifestations in dermatomyositis","volume":"2","author":"Muro","year":"2019","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BOR.0000000000000905","article-title":"Biomarkers of disease activity in dermatomyositis","volume":"34","author":"Lu","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s42358-019-0071-y","article-title":"Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis","volume":"59","author":"Shinjo","year":"2019","journal-title":"Adv. Rheumatol."},{"key":"ref_136","first-page":"395","article-title":"Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis","volume":"25","author":"Roux","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The Diagnosis and Treatment of Antisynthetase Syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin. Pulm. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.41088","article-title":"Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot","volume":"72","author":"Mecoli","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2169\/internalmedicine.7824-21","article-title":"A Comparison of Line Blots, Enzyme-linked Immunosorbent, and RNA-immunoprecipitation Assays of Antisynthetase Antibodies in Serum Samples from 44 Patients","volume":"61","author":"Shinoda","year":"2022","journal-title":"Intern. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-021-08920-y","article-title":"An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations","volume":"63","author":"Fredi","year":"2022","journal-title":"Clin. Rev. Allergy Immunol"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s10067-021-05667-x","article-title":"Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: Results from clinical applications based on a myositis-specific antibody","volume":"40","author":"Yan","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_144","first-page":"176","article-title":"Autoantibody testing in patients with myositis: Clinical accuracy of a multiparametric line immunoassay","volume":"35","author":"Ghirardello","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","article-title":"Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies","volume":"10","author":"Mahler","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"26552","DOI":"10.18632\/oncotarget.15716","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: Proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.15128","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody as a biomarker in patients with dermatomyositis","volume":"47","author":"Shimizu","year":"2020","journal-title":"J. Derm."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/rheumatology\/keac288","article-title":"ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis","volume":"61","author":"Selickaja","year":"2022","journal-title":"Rheumatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/rheumatology\/kev247","article-title":"High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis","volume":"54","author":"Muro","year":"2015","journal-title":"Rheumatology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: Case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1019972","DOI":"10.3389\/fimmu.2022.1019972","article-title":"Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2022.04.017","article-title":"Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review","volume":"101","author":"Genre","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"866701","DOI":"10.3389\/fimmu.2022.866701","article-title":"Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease","volume":"13","author":"Szczesny","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR Myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3899\/jrheum.141307","article-title":"Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue","volume":"42","author":"Peng","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","article-title":"Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease","volume":"19","author":"Enomoto","year":"2017","journal-title":"Arthritis Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3899\/jrheum.170997","article-title":"Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases","volume":"45","author":"Kawasumi","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/mus.27157","article-title":"Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis","volume":"63","author":"Paul","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5\u2019-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Parkes, J.E., Thoma, A., Lightfoot, A.P., Day, P.J., Chinoy, H., and Lamb, J.A. (2020). MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies. BMC Rheumatol., 4.","DOI":"10.1186\/s41927-020-00125-8"},{"key":"ref_174","first-page":"2058739220942340","article-title":"Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives","volume":"18","author":"Barbone","year":"2020","journal-title":"Eur. J. Inflamm."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-12-804279-3.00009-5","article-title":"Cerebrospinal fluid findings in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathies","volume":"146","author":"Illes","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jns.12104","article-title":"Cytoalbuminologic dissociation in Asian patients with Guillain-Barr\u00e9 and Miller Fisher syndromes","volume":"20","author":"Wong","year":"2015","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/ene.14600","article-title":"Cerebrospinal fluid protein in Guillain-Barr\u00e9 syndrome: Need for age-dependent interpretation","volume":"28","author":"Hegen","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0404.2011.01511.x","article-title":"Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"125","author":"Zhang","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1331.2007.01761.x","article-title":"Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients","volume":"14","author":"Jin","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: Pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Walgaard","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.jmb.2016.05.020","article-title":"Gangliosides of the Vertebrate Nervous System","volume":"428","author":"Schnaar","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2014.09.012","article-title":"Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis","volume":"277","author":"Yan","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ajpath.2012.06.034","article-title":"Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier","volume":"181","author":"Devaux","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00134-005-2736-8","article-title":"Anti-phospholipid antibodies in serum from patients with Guillain-Barr\u00e9 syndrome","volume":"31","author":"Nakos","year":"2005","journal-title":"Intensive Care Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(83)91113-3","article-title":"Antiphospholipid antibodies in acute Guillain-Barr\u00e9 syndrome","volume":"2","author":"Harris","year":"1983","journal-title":"Lancet"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ana.410110112","article-title":"In vivo demyelinating activity of sera from patients with Guillain-Barr\u00e9 syndrome","volume":"11","author":"Saida","year":"1982","journal-title":"Ann. Neurol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.410290410","article-title":"In vitro demyelination by serum antibody from patients with Guillain-Barr\u00e9 syndrome requires terminal complement complexes","volume":"29","author":"Clark","year":"1991","journal-title":"Ann. Neurol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.4049\/jimmunol.136.12.4456","article-title":"Activated terminal complement in cerebrospinal fluid in Guillain-Barr\u00e9 syndrome and multiple sclerosis","volume":"136","author":"Sanders","year":"1986","journal-title":"J. Immunol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neulet.2010.08.060","article-title":"Protein profiling of Guillain-Barr\u00e8 syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry","volume":"485","author":"Franciotta","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1007\/s10072-021-05108-2","article-title":"Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barr\u00e9 syndrome and their correlations with clinical features","volume":"42","author":"Liu","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/jnnp.74.7.971","article-title":"Apolipoprotein E genotypes and clinical outcome in Guillain-Barr\u00e9 syndrome","volume":"74","author":"Pritchard","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2009.04.022","article-title":"Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barr\u00e9 syndrome and other neurological disorders","volume":"405","author":"Chiang","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/brain\/103.3.579","article-title":"Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis","volume":"103","author":"Compston","year":"1980","journal-title":"Brain"},{"key":"ref_197","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin. Exp. Immunol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Carr, A.S., Cardwell, C.R., McCarron, P.O., and McConville, J. (2010). A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-46"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF01959485","article-title":"Early-onset myasthenia gravis: Clinical characteristics and response to therapy","volume":"150","author":"Batocchi","year":"1990","journal-title":"Eur J. Pediatr."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archneur.56.1.25","article-title":"Late-onset myasthenia gravis: A changing scene","volume":"56","author":"Aarli","year":"1999","journal-title":"Arch. Neurol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"F. Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neurol.2008.11.020","article-title":"Anticorps dans la myasth\u00e9nie","volume":"165","author":"Eymard","year":"2009","journal-title":"Rev. Neurol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Burden, S.J., Yumoto, N., and Zhang, W. (2013). The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a009167"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies--a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"577076","DOI":"10.1016\/j.jneuroim.2019.577076","article-title":"A novel MuSK cell-based myasthenia gravis diagnostic assay","volume":"337","author":"Han","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/WNL.57.9.1579","article-title":"Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?","volume":"57","author":"Buckley","year":"2001","journal-title":"Neurology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-Titin Antibodies in Myasthenia Gravis: Tight Association With Thymoma and Heterogeneity of Nonthymoma Patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cca.2022.01.004","article-title":"The role of serum free light chain as biomarker of Myasthenia Gravis","volume":"528","author":"Gambino","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Di Stefano, V., Alonge, P., Rini, N., Militello, M., Lupica, A., Torrente, A., and Brighina, F. (2023). Efgartigimod beyond myasthenia gravis: The role of FcRn-targeting therapies in stiff-person syndrome. J. Neurol.","DOI":"10.1007\/s00415-023-11970-1"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s11306-011-0364-6","article-title":"Serum metabolomics for the diagnosis and classification of myasthenia gravis","volume":"8","author":"Lu","year":"2011","journal-title":"Metabolomics"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1212\/NXI.0000000000000945","article-title":"Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"100111","DOI":"10.1016\/j.jtauto.2021.100111","article-title":"Calprotectin as potential novel biomarker in myasthenia gravis","volume":"4","author":"Stascheit","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.13510","article-title":"Circulating microRNAs as potential biomarkers in myasthenia gravis patients","volume":"1412","author":"Punga","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis\u2020","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Vinciguerra, C., Bevilacqua, L., Lupica, A., Ginanneschi, F., Piscosquito, G., Rini, N., Rossi, A., Barone, P., Brighina, F., and Di Stefano, V. (2023). Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows. Brain Sci., 13.","DOI":"10.3390\/brainsci13091286"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/jnnp-2021-326480","article-title":"Using AChR antibody titres to predict treatment responses in myasthenia gravis","volume":"92","author":"Vincent","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria\u2014Methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874312901206010054","article-title":"Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups","volume":"6","author":"Volochayev","year":"2012","journal-title":"Open Rheumatol. J."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","article-title":"Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis","volume":"36","author":"Srivastava","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.semarthrit.2021.03.012","article-title":"Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review: Systematic review","volume":"51","author":"Vulsteke","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jtauto.2022.100148","article-title":"Positioning of myositis-specific and associated autoantibody (MSA\/MAA) testing in disease criteria and routine diagnostic work-up","volume":"5","author":"Bonroy","year":"2022","journal-title":"J. Transl. Autoimmun."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Reed, A.M., Crowson, C.S., Hein, M., de Padilla, C.L., Olazagasti, J.M., Aggarwal, R., Ascherman, D.P., Levesque, M.C., and Oddis, C.V. (2015). Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord., 16.","DOI":"10.1186\/s12891-015-0710-3"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Bobirca, A., Alexandru, C., Musetescu, A.E., Bobirca, F., Florescu, A.T., Constantin, M., Tebeica, T., Florescu, A., Isac, S., and Bojinca, M. (2022). Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge. Life, 12.","DOI":"10.3390\/life12081108"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"101503","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pr. Res. Clin. Rheumatol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Hong","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"7948095","DOI":"10.1155\/2020\/7948095","article-title":"Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis","volume":"2020","author":"Shen","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cei.13404","article-title":"A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis","volume":"199","author":"Peng","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/1759720X16655126","article-title":"Selected aspects of the current management of myositis","volume":"8","author":"Lilleker","year":"2016","journal-title":"Adv. Musculoskelet Dis."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1093\/ejcts\/ezt641","article-title":"Thymectomy in myasthenia gravis: Proposal for a predictive score of postoperative myasthenic crisis","volume":"45","author":"Leuzzi","year":"2014","journal-title":"Eur. J. Cardiothorac Surg."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Wei, B., Lu, G., and Zhang, Y. (2023). Predictive factors for postoperative myasthenic crisis in patients with myasthenia gravis. Interdiscip. Cardiovasc. Thorac. Surg., 36.","DOI":"10.1093\/icvts\/ivad040"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Di Stefano, V., Tubiolo, C., Gagliardo, A., Presti, R.L., Montana, M., Todisco, M., Lupica, A., Caimi, G., Tassorelli, C., and Fierro, B. (2022). Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study. Brain Sci., 12.","DOI":"10.3390\/brainsci12111439"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/20\/2456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:07:13Z","timestamp":1760130433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/20\/2456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":240,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cells12202456"],"URL":"https:\/\/doi.org\/10.3390\/cells12202456","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]}}}